Is trazodone 150 mg taken orally at bedtime appropriate for treating insomnia in an otherwise healthy adult?

Trazodone 150 mg at Bedtime for Insomnia: Not Recommended

Trazodone 150 mg should not be used as first-line therapy for primary insomnia in otherwise healthy adults because major clinical guidelines explicitly recommend against its use, citing that harms outweigh benefits despite widespread off-label prescribing. 1

Guideline Position

• The American Academy of Sleep Medicine (2017) and the American College of Physicians (2016) both issued negative recommendations against trazodone 50 mg for insomnia, concluding that the risk-benefit profile is unfavorable and efficacy evidence is insufficient. 1

• Although the guideline specifically addresses 50 mg, the 150 mg dose you are considering is three times higher and falls within the FDA-approved range for depression treatment (150–400 mg/day in divided doses), not insomnia. 2

• Trazodone is not FDA-approved for insomnia; all use for sleep is off-label. 12

Evidence Quality and Efficacy Concerns

• A 2024 meta-analysis of 44 RCTs (3,935 participants) found that trazodone did not significantly increase subjective total sleep time (mean difference 0.73 minutes, p = 0.96), though it improved sleep quality scores and objective polysomnographic measures. 3

• The most recent systematic review (2023) concluded that a panel of key opinion leaders agreed with the statement that trazodone should never be used as first-line therapy based on limited published evidence supporting its use. 4

• A 2017 systematic review identified only 45 studies over 33 years, with most being small, lacking objective measures, and conducted primarily in depressed populations—not healthy adults with primary insomnia. 5

• A 2005 review stated that "evidence for the efficacy of trazodone in treating insomnia is very limited" and questioned whether the risk/benefit ratio warrants use in nondepressed patients. 6

Safety and Tolerability Issues at 150 mg

• The 2024 meta-analysis found trazodone caused significantly more dropouts due to adverse effects (RR = 2.30,95% CI 1.45–3.64, p < 0.01) and more adverse effects overall (RR = 1.18, p = 0.02). 3

• At 150 mg, expect dose-dependent side effects including marked drowsiness, dizziness, and psychomotor impairment—particularly problematic in older adults. 6

• A 2025 meta-analysis in depressive patients found trazodone significantly increased blurred vision (OR = 17.50), somnolence (OR = 7.34), and sedation (OR = 6.53). 7

• Observational data cited by the American College of Physicians link sedating medications (including trazodone) to increased risk of dementia, falls, fractures, and major injuries, especially in older adults. 1

Special Concern: Alcohol Use

• A 2025 review warns that trazodone's metabolite meta-chlorophenylpiperazine induces increased alcohol craving and use in patients with alcohol use disorder, making it particularly unsuitable if any alcohol consumption is present. 8

Evidence-Based First-Line Alternatives

Instead of trazodone 150 mg, use guideline-recommended first-line agents 1:

For Sleep Onset and Maintenance

• Eszopiclone 2–3 mg – Most robust evidence for both acute and long-term treatment with sustained efficacy beyond 4 weeks. 1
• Zolpidem 10 mg (5 mg in women) – Effective for sleep onset and maintenance in acute treatment. 1
• Suvorexant 10–20 mg – Orexin-receptor antagonist with better tolerability and preserved natural sleep architecture. 1

For Sleep Onset Only

• Ramelteon 8 mg – Melatonin-receptor agonist with no abuse potential, safe for long-term use, though less effective than benzodiazepine-receptor agonists. 19

For Sleep Maintenance Only

• Doxepin 3–6 mg – Low-dose tricyclic with favorable tolerability specifically for sleep maintenance. 1

Clinical Algorithm

1. Screen for comorbidities: If depression, anxiety, or other psychiatric conditions are present, treat the underlying disorder first—this may resolve insomnia. 1

2. Prioritize non-pharmacologic therapy: Cognitive-behavioral therapy for insomnia (CBT-I) should be offered as first-line treatment before or alongside any medication. 9

3. Select medication by sleep pattern 1:

   • Sleep-onset difficulty → Ramelteon 8 mg or zolpidem 5–10 mg
   • Sleep-maintenance difficulty → Doxepin 3–6 mg
   • Both onset and maintenance → Eszopiclone 2–3 mg or suvorexant 10–20 mg

4. Avoid trazodone unless the patient has comorbid depression requiring antidepressant therapy at therapeutic doses (150–400 mg/day divided), in which case the sleep benefit is secondary. 2

Common Pitfalls

• Do not prescribe trazodone 150 mg solely for insomnia in a healthy adult—this dose is intended for depression and carries significant adverse-effect burden without proven insomnia efficacy. 12

• Do not assume "commonly prescribed" equals "evidence-based"—trazodone is the second most prescribed sleep medication despite negative guideline recommendations. 46

• Do not use trazodone in older adults due to heightened fall risk, cognitive impairment, and anticholinergic effects. 1

• Do not combine hypnotics—no evidence supports combination therapy, and concomitant use multiplies safety risks. 1